Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
04 oct. 2023 07h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
12 sept. 2023 09h25 HE
|
Gain Therapeutics, Inc.
First drug candidate identified with Gain’s proprietary computational drug discovery platform SEE-Tx® to enter clinical development phase BETHESDA, Md., Sept. 12, 2023 (GLOBE...
Brain Implants Market to hit USD 10 billion by 2032, says Global Market Insights Inc.
10 sept. 2023 19h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Brain Implants Market size is expected to be worth USD 10 billion by 2032. The growing burden of neurological disorders along with the...
Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®
28 août 2023 07h00 HE
|
PHARMA TWO B LTD
Sub-group analyses of patients with early Parkinson's disease (PD) at different age groups or baseline disease severities who were treated with P2B001 showed consistently greater symptomatic control...
Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease
22 août 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has...
Deep Brain Stimulation Market worth $1.15 Billion by 2030 - Exclusive Report by The Insight Partners
16 août 2023 08h37 HE
|
The Insight Partners
Pune, India, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Deep brain stimulator (DBS) is a device comprising a brain-oriented pacemaker (an implantable pulse generator) that sends electrical stimulation via...
RaceTrac’s Run For Research 5K Returns to Truist Park September 16
03 août 2023 14h00 HE
|
Racetrac, Inc.
ATLANTA, GA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- According to The Michael J. Fox Foundation for Parkinson’s Research (MJFF), six million people worldwide live with Parkinson’s disease. One million of...
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
28 juin 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal...
Nature Publishes Work Demonstrating Clinical ink Technology Sensitivity to Parkinson’s Disease
15 mai 2023 13h30 HE
|
Clinical Ink
Winston Salem, NC, May 15, 2023 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, announces the publication of “Using a smartwatch and smartphone to assess early...
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease
25 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Parkinson’s disease (“PD”), the second leading cause of neurodegeneration in the world, is characterized by progressive degeneration of nigrostriatal dopaminergic neurons and intracellular...